Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Apr 17, 2015 3:34pm

285 Views

Post# 23641875

RE:RE:RE:RE:RE:when you have an infestestation...

Thanks, Fouremm. You're an honest guy I can tell.

I think you are right that they know the revised MofA. And so does BjC. That's a major theme of his analyst write up (the potential explanation he offered that is). Supported by the data from Emerald Logic I believe.

I believe that we are now - Finally - in a very good position with respect to this company. I think the prospects going forward are very, very promising and that this stock is significantly undervalued. Obviously, BjC agrees with that, as do most shareholders on this board.

I bet we will be back about $3 CAD before long.

IMHO. DYODD. GLTA.

Bullboard Posts

MDA Space stock blasts off on Q3 financial results